-
Annual sales of 2 billion is not enough! Tonghua Dongbao's territory of lowering blood sugar wants to add many powerful generals
Time of Update: 2017-11-27
On November 9, Tonghua Dongbao announced that the clinical trial application for the recombinant insulin raw material and injection developed by the company has been accepted On November 16, the compa
-
Viewing the status quo of antidepressant research and development from the application and approval data
Time of Update: 2017-11-24
With the improvement of people's life quality, people begin to pay attention to their spiritual world Depression is also slowly coming into people's vision In February this year, the World Health Orga
-
Sales down 21% + six new hepatitis C drugs approved, interferon market is facing strong impact!
Time of Update: 2017-11-24
In October 2016, CDE announced the inclusion of new anti hepatitis C drugs in the priority review process, so that the registration application of such drugs can enter the fast lane In 2017, CFDA succ
-
Clinical research progress of China's Class 1 new drugs in 2017
Time of Update: 2017-11-23
Since March 4, 2016, CFDA issued the work plan on the reform of chemical drug registration and classification, China's class 1 innovative drug has been redefined as unlisted at home and abroad, which
-
Amlodipine competes fiercely with a 20 billion fast-moving retail terminal of blood pressure reduction
Time of Update: 2017-11-23
In recent years, the market of high blood pressure drugs has been growing under the huge demand of high blood pressure people in China However, in 2015-2016, the overall growth rate of hypertension dr
-
Drug companies throw 7.8 billion "snake swallows elephant" and their net profit soars from 10 million to 1 billion?
Time of Update: 2017-11-22
Highlights Recently, Furen Pharmaceutical Group Industrial Co., Ltd (hereinafter referred to as Furen pharmaceutical) announced that it plans to purchase 100% equity of Kaifeng Pharmaceutical (Group)
-
"Big pattern" in small fields: the present and future of drugs for the treatment of atopic dermatitis
Time of Update: 2017-11-21
Atopic dermatitis (AD), also known as allergic eczema, is a skin inflammation Ad is usually associated with other allergic diseases, such as allergic rhinitis and asthma It is believed that ad is rela
-
Growth trajectory of eight representative varieties of Indigenous Innovation Medicine
Time of Update: 2017-11-17
Recently, the general office of the CPC Central Committee and the general office of the State Council issued the opinions on deepening the reform of the review and approval system and encouraging the
-
The original research patent expires without price reduction, and the spring of domestic pulmonary hypertension generic drugs is coming!
Time of Update: 2017-11-17
Pulmonary hypertension (PH) is a kind of pulmonary vascular disease that can not be cured completely at present, and it also needs to be taken for life Before that, bosentan tablet was the main drug f
-
21.1 billion yuan domestic market of lipid regulating drugs, 80% of which
Time of Update: 2017-11-17
In the future, blood lipid regulating drugs will still be the mainstream products of cardiovascular and cerebrovascular drugs Among them, "statins" are commonly used clinical drugs, accounting for 84.
-
"Diabetes Day" market: more than 100 million patients, more than 10 billion retail sales, top 10 brand foreign investment accounted for 7 seats
Time of Update: 2017-11-14
Today, we usher in the 11th "United Nations Diabetes Day" Diabetes is a common endocrine and metabolic disease Its basic pathological characteristics are a series of metabolic disorders such as glucos
-
These 36 varieties will pass the consistency evaluation first! The generic market has changed
Time of Update: 2017-11-12
As of October 15, 2017, at least 35 be tests have been completed, more than 30 varieties have been submitted to CDE for acceptance, and the first wave of beach grabber is coming in the wave of consist
-
Hepatitis B drugs on the market and under research in China
Time of Update: 2017-11-10
Market outlook: according to the World Health Organization's global hepatitis report 2017 released in April this year, the number of people infected with hepatitis B or C globally has exceeded 325 mil
-
7 billion yuan osteoporosis drug retail market, competing for success!
Time of Update: 2017-11-08
In recent years, the prevalence of osteoporosis is increasing gradually, and the market potential of drugs is huge According to the data of Zhongkang CMH, the total scale of osteoporosis drug market i
-
One product soared by 150%! New antithrombotic varieties are growing rapidly
Time of Update: 2017-11-07
Medical research shows that the formation of vascular embolism is a changing process under the interaction of genetic factors and environmental factors Vascular embolism has complex characteristics of
-
With an annual increase of 100000 new patients, China has become the "largest country of Parkinson's disease". How has the drug market performed in recent years?
Time of Update: 2017-11-06
According to the statistics of the world Parkinson disease association, the incidence rate of Parkinson disease is 1.7% among people over 65 years old, and the incidence rate is 70 3-5% At present, th
-
Timeline of M & A: a brief history of the expansion of cro enterprises in China, and how does Wuxi apptec and tiger medicine "eat fat"
Time of Update: 2017-11-06
2017 is a memorable year in the history of China's cro development The domestic cro industry is going through the stage of market integration through listing and M & A This paper will summarize some t
-
China's 30 billion Lung Cancer market, targeting drugs
Time of Update: 2017-11-05
The World Lung Cancer Alliance launched a global initiative in November 2001, which designated November as the "global lung cancer concern month" Over the years, the incidence rate and mortality rate
-
50 billion antidiabetic drugs market is growing, top 10 brands take over half of the market
Time of Update: 2017-11-02
Wonderful content: on March 13 this year, AstraZeneca's new diabetes drug, dagreen, was approved by CFDA and became the first sglt-2 inhibitor approved for listing in China On September 21, the listin
-
Anti hyperuricemic gout has a billion market in China! Still growing fast!
Time of Update: 2017-11-01
According to the "consensus of Chinese experts on hyperuricemia and gout treatment" released by the endocrinology branch of the Chinese Medical Association, at present, China's hyperuricemia (Hua) has
